Management of the patient after heart transplant

  • Michael A. Mathier
  • Dennis M. McNamara


Cardiac transplantation is a highly effective therapy for selected patients with end-stage cardiac disease. The management of the patient after heart transplant involves three main strategies: optimization of immunosuppressive therapy, prevention of complications resulting from the transplant or the immunosuppressive agents, and treatment of those complications when they arise. For most patients, optimal current immunosuppression in the first year after transplantation consists of combination therapy with a calcineurin inhibitor (eg, cyclosporine or tacrolimus), corticosteroids, and an antimetabolite agent (eg, azathioprine or mycophenolate mofetil). Ideally, the corticosteroid is weaned and discontinued 1 to 2 years following transplantation and the patient is managed chronically with a two-drug immunosuppressive regimen. The major complications that occur following cardiac transplantation include infection, hypertension, diabetes, dyslipidemia, osteoporosis, graft coronary disease, renal insufficiency, and malignancy. Preventive efforts focused on infection, osteoporosis, renal insufficiency, and malignancy include minimization of immunosuppression. Once established, treatment of any of the above conditions generally relies on standard pharmacologic therapies; however, an understanding of potential drug interactions is critical. In addition, although standard nonpharmacologic therapies may be used to treat several of these conditions, one must be cognizant of special issues related to the post-transplant state.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Taylor DO, Edwards LB, Mohacsi PJ, et al.: The Registry of the International Society for Heart and Lung Transplantation: Twentieth Official Adult Heart Transplant Report-2003. J Heart Lung Transplant 2003, 22:616–624. The most recent report from the International Society for Heart and Lung Transplantation registry on adult heart transplant. Reviews trends in volume, patient and donor characteristics, and outcomes, including the relative importance of various post-transplant medical conditions.PubMedCrossRefGoogle Scholar
  2. 2.
    International Society for Heart and Lung Transplant. http:/ Accessed June 1, 2004.Google Scholar
  3. 3.
    Brann WM, Bennett LE, Keck BM, Hosenpud JD: Morbidity, functional status, and immunosuppressive therapy after heart transplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant 1998, 17:374–382.PubMedGoogle Scholar
  4. 4.
    Kobashigawa JA, Katznelson S, Laks H, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621–627.PubMedCrossRefGoogle Scholar
  5. 5.
    Jimenez J, Kapadia SR, Yamani MH, et al.: Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant 2001, 20:393–398.PubMedCrossRefGoogle Scholar
  6. 6.
    Valantine H: Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004, 23(5 suppl):S187-S193. A thorough review of the current status of graft coronary disease.PubMedCrossRefGoogle Scholar
  7. 7.
    Subramanian AK, Quinn TC, Kickler TS, et al.: Correlation of chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation. Transplantation 2002, 73:761–764.PubMedCrossRefGoogle Scholar
  8. 8.
    Schwaiblmair M, von Scheidt W, Uberfuhr P, et al.: Lung function and cardiopulmonary exercise performance after heart transplantation: influence of cardiac allograft vasculopathy. Chest 1999, 116:332–339.PubMedCrossRefGoogle Scholar
  9. 9.
    Aranda JM, Pauly DF, Kerensky RA, et al.: Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy. J Heart Lung Transplant 2002, 21:860–866.PubMedCrossRefGoogle Scholar
  10. 10.
    Schnetzler B, Drobinski G, Dorent R, et al.: The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 2000, 19:557–565.PubMedCrossRefGoogle Scholar
  11. 11.
    Cardillo M, Rossini G, Scalamogna M, et al.: Tumor incidence in heart transplant patients: report of the North Italy Transplant Program Registry. Transplant Proc 2001, 33:1840–1843.PubMedCrossRefGoogle Scholar
  12. 12.
    Fortina AB, Caforio AL, Piaserico S, et al.: Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000, 19:249–255.PubMedCrossRefGoogle Scholar
  13. 13.
    Jemec GBE, Holm EA: Nonmelanoma skin cancer in organ transplant patients. Transplantation 2003, 75:253–257.PubMedCrossRefGoogle Scholar
  14. 14.
    Gao SZ, Chaparro SV, Perlroth M, et al.: Post-transplantation lymphoproliferative disease in heart and heartlung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003, 22:505–514.PubMedCrossRefGoogle Scholar
  15. 15.
    Demers P, Moffatt S, Oyer PE, et al.: Long-term results of heart transplantation in patients older than 60 years. J Thorac Cardiovasc Surg 2003, 126:224–231.PubMedCrossRefGoogle Scholar
  16. 16.
    Caforio AL, Fortina AB, Piaserico S, et al.: Skin cancer in heart transplant recipients. Circulation 2000, 102(suppl 3):III222-III227.PubMedGoogle Scholar
  17. 17.
    Zilz ND, Olson LJ, McGregor CG: Treatment of posttransplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001, 20:770–772.PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor DO, Barr ML, Radovancevic B, et al.: A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999, 18:336–345.PubMedCrossRefGoogle Scholar
  19. 19.
    Kobashigawa J, Miller L, Relund D, et al.: A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998, 66:507–515.PubMedCrossRefGoogle Scholar
  20. 20.
    Mancini D, Pinney S, Burkhoff D, et al.: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48–53.PubMedCrossRefGoogle Scholar
  21. 21.
    Rubin RH: Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000, 19:731–735.PubMedCrossRefGoogle Scholar
  22. 22.
    Keay S: Cardiac transplantation: pre-transplant infectious diseases evaluation and post-transplant prophylaxis. Curr Infect Dis Rep 2002, 4:285–292. An exhaustive review of current understanding and practice patterns for the management of the infectious complications of cardiac transplantation and immunosuppression.PubMedCrossRefGoogle Scholar
  23. 23.
    Egan JJ, Carroll KB, Yonan N, et al.: Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant 2002, 21:460–466.PubMedCrossRefGoogle Scholar
  24. 24.
    Eisen HJ: Hypertension in heart transplant recipients: more than just cyclosporine. J Am Coll Cardiol 2003, 41:433–434.PubMedCrossRefGoogle Scholar
  25. 25.
    Andreassen AK, Hartmann A, Offstad J, et al.: Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. J Am Coll Cardiol 1997, 29:1324–1331.PubMedCrossRefGoogle Scholar
  26. 26.
    Brozena SC, Johnson MR, Ventura H, et al.: Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. J Am Coll Cardiol 1996, 27:1707–1712.PubMedCrossRefGoogle Scholar
  27. 27.
    Lang CC, Beniaminovitz A, Edwards N, Mancini DM: Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant 2003, 22:244–249.PubMedCrossRefGoogle Scholar
  28. 28.
    Marchetti P: New-onset diabetes after transplantation. J Heart Lung Transplant 2004, 23(5 suppl):S194-S201.PubMedCrossRefGoogle Scholar
  29. 29.
    Davidson J, Wilkinson A, Dantal J, et al.: New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003, 75(suppl):SS3-S24.PubMedCrossRefGoogle Scholar
  30. 30.
    Fatemeh A, Jackson CH, Parameshwar J, et al.: Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 2003, 73:1258–1264.Google Scholar
  31. 31.
    Pflugfelder PW, Huff M, Oskalns R, et al.: Cholesterollowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995, 14:613–622.PubMedGoogle Scholar
  32. 32.
    Wenke K, Meiser B, Thiery J, et al.: Simvastatin initiated early after heart transplantation. Circulation 2003, 107:93–97.PubMedCrossRefGoogle Scholar
  33. 33.
    Keogh A, Macdonald P, Kaan A, et al.: Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000, 19:529–537.PubMedCrossRefGoogle Scholar
  34. 34.
    Bonet LA, Martinez-Dolz L, Vives MA, et al.: Lipidlowering effect of atorvastatin in heart transplantation. Transplant Proc 2002, 34:179–181.CrossRefGoogle Scholar
  35. 35.
    Weis M, Pehlivanli S, Meiser BM, von Scheidt W: Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001, 38:814–818.PubMedCrossRefGoogle Scholar
  36. 36.
    Eisen HJ, Tuzcu EM, Dorent R, et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847–858.PubMedCrossRefGoogle Scholar
  37. 37.
    Doshi AA, Rogers J, Kern MJ, Hauptman PJ: Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy. Am J Cardiol 2004, 93:90–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Grise MA, Reilly JP, Tobis JM, et al.: Intracoronary radiation to treat in-stent restenosis in six cardiac transplant patients. Catheter Cardiovasc Interv 2003, 60:41–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Ono M, Michler RE: Beating heart coronary artery bypass surgery after orthotopic heart transplantation. J Card Surg 2003, 18:545–549.PubMedCrossRefGoogle Scholar
  40. 40.
    Aleksic I, Piotrowski JA, Kamler M, et al.: Minimally invasive direct coronary artery bypass in a cardiac transplant recipient with allograft vasculopathy. Ann Thorac Surg 2004, 77:1433–1434.PubMedCrossRefGoogle Scholar
  41. 41.
    Radovancevic B, McGiffin DC, Kobashigawa JA, et al.: Reptransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. J Heart Lung Transplant 2003, 22:862–868.PubMedCrossRefGoogle Scholar
  42. 42.
    Sehgal V, Radhakrishnan J, Appel GB, et al.: Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids and hypertension. Am J Kidney Dis 1995, 26:193–201.PubMedGoogle Scholar
  43. 43.
    Vossler MR, Ni H, Toy W, Hershberger RE: Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation. J Heart Lung Transplant 2002, 21:874–881.PubMedCrossRefGoogle Scholar
  44. 44.
    Goldstein DJ, Zuech N, Sehgal V, et al.: Cyclosporineassociated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997, 63:664–668.PubMedCrossRefGoogle Scholar
  45. 45.
    Van GelderT, Balk AH, Zietse R, et al.: Survival of heart transplant recipients with cyclosporine-induced renal insufficiency. Transplant Proc 1998, 30:1122–1123.PubMedCrossRefGoogle Scholar
  46. 46.
    Satchithananda DK, Parameshwar J, Sharples L, et al.: The incidence of end-stage renal failure in 17 years of heart transplantation: a single center experience. J Heart Lung Transplant 2002, 21:651–657.PubMedCrossRefGoogle Scholar
  47. 47.
    Baran DA, Galin ID, Sandler D, et al.: Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. Transplant Proc 2002, 34:1872–1873.PubMedCrossRefGoogle Scholar
  48. 48.
    Groetzner J, Meiser B, Landwehr P, et al.: Mycophenolate mofetil and sirolimus as calcineurin inhibitorfree immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004, 77:568–574.PubMedCrossRefGoogle Scholar
  49. 49.
    Snell GI, Levvey BJ, Chin W, et al.: Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002, 21:540–546.PubMedCrossRefGoogle Scholar
  50. 50.
    Frimat L, Villemot JP, Cormier L, et al.: Treatment of end-stage renal failure after heart transplantation. Nephrol Dial Transplant 1998, 13:2905–2908.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Michael A. Mathier
    • 1
  • Dennis M. McNamara
    • 1
  1. 1.Cardiovascular InstituteUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations